Glutamate Decarboxylase 1 Overexpression as a Poor Prognostic Factor in Patients with Nasopharyngeal Carcinoma

Abstract Background Cranial nerve (CN) palsy due to cancer involvement has been considered as an unfavorable prognostic factor for patients with nasopharyngeal carcinoma (NPC). We assessed the role of IMRT based treatment on the recovery of CN palsy and investigated the prognostic value of complete recovery of CN palsy. Methods A total of 115 NPC patients with cancer-related CN palsy were included in the study. We referred CTCAE version 5.0 to evaluate the grade of CN palsy. Results All patients with grade 1 CN palsy recovered completely during the 2 years of follow-up after definite treatment. Most grade 2 palsy could change gradually to grade 1 palsy or complete recovery during 2 years of follow-up. Patients with more than 2 symptoms of CN palsy had poor 3-year disease-free survival (DFS) than these with 1 or 2 symptoms (60.3% vs. 84.9%, HR 0.25, 95% CI 0.07–0.89, P = 0.001). There were no significant differences for PFS, OS, DMFS and LRFS between patients with complete recovery and non-complete recovery from CN palsy after receiving IMRT based comprehensive treatment. Conclusions IMRT based comprehensive treatment could effectively promote the recovery of tumor-related CN palsy for NPC patient. More than 2 symptoms of CN palsy was a poor prognostic factor for DFS of NPC patients. The prognostic role of complete recovery of CN palsy was not identified in our study.

Download Full-text

Discrepant expression and prognostic role of epidermal growth factor receptor and icotinib radiosensitization for nasopharyngeal carcinoma

10.21203/rs.3.rs-20637/v1 ◽

2020 ◽

Author(s):

Bo Wu ◽

Hua-cai Xiong ◽

Yong Wang ◽

Hong-sheng Lu ◽

Qi Chen ◽

...

Keyword(s):

Epidermal Growth Factor Receptor ◽

Growth Factor ◽

Prognostic Factor ◽

Nasopharyngeal Carcinoma ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Disease Free Survival ◽

Poor Prognostic Factor ◽

Egfr Expression ◽

Epidermal Growth

Abstract Background: Epidermal growth factor receptor (EGFR) expression was observed in many tumors. Icotinib (IH), an EGFR tyrosine kinase inhibitor, could enhance the radiosensitivity, but few studies have focused on nasopharyngeal carcinoma (NPC). Materials and Methods : One hundred fifteen NPC lesions and 30 nasopharyngitis lesions were enrolled for EGFR expression evaluation with immunohistochemical staining. The correlation of EGFR expression and clinical parameters was analyzed. Survival analysis was calculated using univariate and multivariate analysis. A radioresistant NPC cell line, CNE-2R, was established with a gradient irradiation schedule of 60 Gy from CNE-2. Cell viability of CNE-2/2R was detected using microculture tetrazolium assay and colony-forming assay. The IH radiosensitization effect and EGFR expression were also evaluated in CNE-2/2R. Results: High EGFR expression was more frequently detected in NPC lesions (73/115) than chronic nasopharyngitis lesions (5/30, p =0.000). EGFR expression was correlated with tumor stage ( p =0.000) and tumor-node-metastasis (TNM) stage ( p =0.006). EGFR expression was an independent prognostic factor of disease-free survival ( p =0.047) and overall survival ( p =0.016). The optical density value of CNE-2R was higher than CNE-2 on days 1, 2, 4, and 6 after radiation of 4 Gy ( p <0.005). CNE-2 colony numbers clearly decreased compared with CNE-2R ( p <0.05), and IH enhanced the radiosensitizing effect of CNE-2R with an apparently lower survival fraction (1.414 times, p <0.05). Higher EGFR expression was observed in CNE-2R cells and decreased accordingly when exposed to IH. Conclusion: High EGFR expression was more frequently detected as a poor prognostic factor in NPC patients. Higher radioresistance and EGFR expression were observed in CNE-2R, and IH could reduce it. These results provided a new theoretical basis for clinical application of icotinib radiosensitization in NPC radiotherapy.

Download Full-text

AMACR overexpression as a poor prognostic factor in patients with nasopharyngeal carcinoma

Tumor Biology ◽

10.1007/s13277-014-2065-z ◽

2014 ◽

Vol 35 (8) ◽

pp. 7983-7991 ◽

Cited By ~ 4

Author(s):

Ying-En Lee ◽

Hong-Lin He ◽

Sung-Wei Lee ◽

Tzu-Ju Chen ◽

Kwang-Yu Chang ◽

...

Keyword(s):

Prognostic Factor ◽

Nasopharyngeal Carcinoma ◽

Poor Prognostic Factor

Download Full-text

Obstructive sleep apnea syndrome may be a poor prognostic factor in allergic rhinitis: A mini-review and hypothesis

10.26226/morressier.5acc8ad0d462b8028d89ada0 ◽

2018 ◽

Author(s):

Sun Qingjia

Keyword(s):

Obstructive Sleep Apnea ◽

Allergic Rhinitis ◽

Sleep Apnea ◽

Prognostic Factor ◽

Obstructive Sleep Apnea Syndrome ◽

Sleep Apnea Syndrome ◽

Poor Prognostic Factor ◽

Obstructive Sleep ◽

Apnea Syndrome

Download Full-text

Combination of GP88 Expression in Tumor Cells and Tumor-Infiltrating Immune Cells Is an Independent Prognostic Factor for Bladder Cancer Patients

Cells ◽

10.3390/cells10071796 ◽

2021 ◽

Vol 10 (7) ◽

pp. 1796

Author(s):

Markus Eckstein ◽

Verena Lieb ◽

Rudolf Jung ◽

Danijel Sikic ◽

Katrin Weigelt ◽

...

Keyword(s):

Bladder Cancer ◽

Prognostic Factor ◽

Tumor Cells ◽

Immune Cells ◽

Potential Candidate ◽

Poor Prognostic Factor ◽

Risk Of Death ◽

Increased Risk ◽

Muscle Invasive ◽

Disease Specific

Urothelial bladder cancer (BCa) is the ninth most commonly diagnosed cancer worldwide and accounts for approximately 3% of global cancer diagnoses. We are interested in prognostic markers that may characterize tumor cells (TCs) and immune cells (ICs) and their relationship in BCa. A potential candidate marker that meets these criteria is progranulin (GP88), which is expressed separately in TCs and ICs. We analyzed GP88 expression by immunohistochemistry (IHC) in 196 muscle-invasive BCa samples using a tissue microarray. The immunoreactive score for GP88 staining in TCs and the percentage of GP88-positive ICs was determined. An easy cutoff for the staining status of TCs (positive vs. negative) and ICs (0% vs. >0%) and, more generally, negative vs. positive GP88 staining could be applied. We detected 93 patients (47.4%) and 92 patients (46.9%) with GP88-positive TCs or ICs, respectively. The IHC results were correlated with clinicopathological and survival data. Positive GP88 staining in TCs appeared to be an independent poor prognostic factor for disease-specific survival (DSS) (RR (relative risk) = 1.74; p = 0.009) and recurrence-free survival (RFS) (RR = 1.92; p = 0.002). In contrast, negative GP88 staining in ICs was an independent negative predictor for overall survival (OS) (RR = 2.18; p < 0.001), DSS (RR = 2.84; p < 0.001) and RFS (RR = 2.91; p < 0.001) in multivariate Cox’s regression analysis. When combining GP88 staining in TCs and ICs, a specific combination of GP88-positive TCs and GP88-negative ICs was associated with a 2.54-fold increased risk of death, a 4.21-fold increased risk of disease-specific death and a 4.81-fold increased risk of recurrence compared to GP88-negative TCs and GP88-positive ICs. In summary, GP88 positivity in TCs is a negative prognostic factor for DSS and RFS. In addition, GP88 positivity can mark ICs that are associated with a good prognosis (OS, DSS and RFS). The combination of GP88 staining in TCs and ICs appears to be a significant independent prognostic biomarker in muscle-invasive BCa.

Download Full-text